Clomipramine/sildenafil

Clomipramine/sildenafil
Combination of
ClomipramineTricyclic antidepressant (TCA), serotonin–norepinephrine reuptake inhibitor (SNRI), other actions
SildenafilPhosphodiesterase PDE5 inhibitor
Clinical data
Other namesCDFR-0812; CDFR0812
Routes of
administration		Oral[1]

Clomipramine/sildenafil (developmental code name CDFR-0812) is a combination of the tricyclic antidepressant (TCA) and serotonin–norepinephrine reuptake inhibitor (SNRI) clomipramine and the phosphodiesterase PDE5 inhibitor and erectile dysfunction drug sildenafil which is under development for the on-demand treatment of premature ejaculation.[1][2][3] It is taken orally.[1] The drug is under development by CTCBIO.[1][2] As of October 2025, it is in phase 3 clinical trials in South Korea.[1][2]

See also

References

  1. ^ a b c d e "Clomipramine/sildenafil". AdisInsight. 9 October 2025. Retrieved 27 January 2026.
  2. ^ a b c "Delving into the Latest Updates on Sildenafil Citrate/Clomipramine Hydrochloride with Synapse". Synapse. 24 May 2025. Retrieved 27 January 2026.
  3. ^ Moon D, Lee W, Kim S, Choi H, Kam S, Kim S, et al. (12 May 2024). "(006) Efficacy and Safety of On-Demand Therapy With Clomipramine/Sildenafil Combination Compared to On-Demand Therapy With Clomipramine or Sildenafil Alone in Patients With Premature Ejaculation: A Prospective, Randomized, Double-Blinded, Active-Controlled". The Journal of Sexual Medicine. 21 (Supplement_6) qdae161.006. doi:10.1093/jsxmed/qdae161.006. ISSN 1743-6095. Retrieved 27 January 2026.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.